Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant Non-Small Cell Lung Cancer After First-Line Treatment With Third-Generation EGFR Tyrosine Kinase Inhibitor Plus Chemotherapy: A National Multicenter, Randomized Controlled Clinical Trial

This national multicenter, randomized controlled clinical trial evaluates the safety and efficacy of consolidative stereotactic radiotherapy in patients with advanced EGFR-mutant non-small cell lung cancer who have oligo-residual disease after four cycles of first-line treatment with third-generation EGFR-TKI plus platinum-based pemetrexed chemotherapy. Eligible participants will be randomized 1:1 to continue third-generation EGFR-TKI plus pemetrexed maintenance therapy alone or to receive stereotactic radiotherapy to all oligo-residual lesions in addition to the same maintenance therapy. The primary endpoint is progression-free survival.

Start Date01 Oct 2026

Sponsor / Collaborator

Fudan University

NCT06694454

/ SuspendedPhase 1/2IIT

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Background:
Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard treatment for people diagnosed with early stages of NSCLC. Despite complete removal of these tumors, many recur (happen again). An FDA-approved drug combination to treat early-stage NSCLC prior to the surgery is durvalumab plus standard chemotherapy. The FDA approved infusion drug azacytidine [AZA] is used to treat several diseases because it can rapidly kill dividing cells (including cancer cells) but it is not approved for NSCLC. An inhaled (aerosolized) form of AZA is also not approved for NSCLC. However, researchers want to know if an inhaled version of AZA can help improve treatment of people with NSCLC because inhaled AZA goes directly into the lungs with limited absorption into the bloodstream.
Objective:
To find the safest and most effective dose of inhaled AZA in participants with early-stage non-small cell lung cancer (NSCLC) that can still be removed by surgery.
Eligibility:
Adults aged 18 and older with operable early-stage NSCLC. Participants will be required to also enroll in NIH protocol 06C0014 which allows for pre- and post-treatment biopsies and bloodwork to be obtained for additional research studies.
Design:
Participants will be screened. They will have a physical exam with blood tests. Their medical records will be reviewed. They will have imaging scans and tests of their heart and lung functions. Participants will be required to have a tissue sample (biopsy) taken of their tumor prior to receiving study drug and again during surgery after Cycle 3; airway tissue biopsies and collection of collect bronchial (lung) fluid may also be done.
Participants will receive the study treatment for 3 cycles. Each cycle is 21 days. They will need to come to the NIH Clinical Center (CC) on days 1-4 of Cycles 1-3.
AZA will be given as a drug mist that can be inhaled (like the type of mist in an asthma inhaler) using a nebulizer at the NIH Clinical Center (CC) for 3 days in a row (consecutive days) during the first week of each cycle. The participant will inhale the AZA drug mist for 20 to 30 minutes each time. Participants will also receive durvalumab and a specific 2-drug assigned chemotherapy by intravenous (IV) infusion on day 4 of each cycle.
Participants will have a follow-up visit 2 weeks after their last dose of study drugs. Then they will have planned surgery to remove the tumors.
Participants will have additional follow-up visits at the NIH CC about 1 and 3 months after the surgery, and then for every 3 months for up to 3 years.

Start Date01 Oct 2026

Sponsor / Collaborator

National Cancer Institute

NCT07777822

/ RecruitingPhase 3

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Start Date14 Aug 2026

Sponsor / Collaborator

Revolution Medicines, Inc.

100 Clinical Results associated with Pemetrexed Disodium Hydrate

100 Translational Medicine associated with Pemetrexed Disodium Hydrate

100 Patents (Medical) associated with Pemetrexed Disodium Hydrate

3,348

Literatures (Medical) associated with Pemetrexed Disodium Hydrate

01 Sep 2026·INTERNATIONAL ENDODONTIC JOURNAL

Development of a Nano‐Hybrid Composite Using Bovine Hydroxyapatite and Montmorillonite for Endodontic Applications—An In Vitro Study

Article

Author: Dias, George ; Ratnayake, Jithendra ; Gould, Maree ; Kumara, P. A. A. S. Prasad ; Cooper, Paul R. ; Cathro, Peter ; Duncan, Henry F.

ABSTRACT:

Aim:

Hydraulic calcium silicate cements are widely employed in endodontics due to their excellent biocompatibility, bioactivity, sealing ability, and remineralisation potential. However, currently used products such as mineral trioxide aggregate (MTA) exhibit several limitations, including discolouration, cost, and poor handling properties. Therefore, this study aimed to develop and characterise a bovine‐derived hydroxyapatite (BHA) and montmorillonite (MMT) nanoclay hybrid composite (BHA‐MMT), incorporating zirconium oxide as a radiopacifier and calcium silicate phases as setting agents.

Methodology:

BHA was produced from waste bovine bones using a defatting and deproteination method. MMT clay was exfoliated into nanoclay using shear force with a planetary ball mill. The composite powders were prepared by combining BHA (20% and 25% wt), zirconium oxide (30% wt), setting agents with exfoliated MMT (15% and 20% wt) to produce three composite materials with different BHA and MMT ratios, namely B20, B25, and M20. The resulting powders were mixed with deionised water to form hydraulic cements. The composite materials were tested for chemical, mechanical, and physical properties compared with the commercially available ProRoot MTA. The biocompatibility, bioactivity, and remineralisation potential of the materials were also examined using established in vitro assays .

Results:

The pH of the material increased above 11 after 24 h and remained constant up to 21 days. The compressive strengths of B20, B25, and M20 were 23.63, 21.2, and 23.8 MPa, respectively, after 21 days. The mean setting time of the composites ranged from 13 to 14 min, and the concentrations of heavy metals were within the permissible limits specified by ISO standards. The experimental composite materials demonstrated radiopacity values within the range, consistent with ISO recommendations. Among the variants, B20 and B25 demonstrated good cell viability, while M20, containing a higher proportion of MMT, showed enhanced apatite formation and remineralization, indicating improved bioactivity.

Conclusion:

The developed BHA–MMT composites demonstrated promising physicochemical, biological, and remineralisation properties consistent with ISO standard requirements. Overall, the product represents a bioactive composite material system; further investigations, including in vivo studies, are necessary to confirm its clinical applicability in vital pulp treatment (direct/indirect pulp capping, pulpotomy) and root‐end filling procedures.

01 Aug 2026·Australian Endodontic Journal

Biological and Mechanical Comparison of Eggshell‐Derived Hydroxyapatite, Calcium Hydroxide, and Mineral Trioxide Aggregate

Article

Author: Gungormus, Mustafa ; Demiral, Ayse ; Aksoy, Merve ; Sari, Makbule Buse Dundar ; Bakirhan, Nurgul K.

ABSTRACT:

This study compared the mechanical properties of eggshell‐derived hydroxyapatite (ESDHA), mineral trioxide aggregate (MTA), and calcium hydroxide (CH), and evaluated their cytotoxicity using human dental pulp stem cells (HDPSCs). Cement samples were prepared and incubated at 37°C under humid conditions. Cytotoxicity was assessed using extracts collected at different setting periods, followed by real‐time cell analysis. Compressive strength was measured at multiple time points. Structural and chemical characterisation was performed using X‐ray diffractometry, Raman spectroscopy, scanning electron microscopy, and energy‐dispersive spectroscopy. ESDHA and MTA showed no cytotoxic effects, whereas CH exhibited initial cytotoxicity with a doubling time of 42.32 ± 1.69 h on day 1. MTA demonstrated the highest compressive strength (85.6 ± 3.2 MPa at 28 days), followed by ESDHA (18.9 ± 1.4 MPa), while CH had the lowest strength (5.1 ± 0.4 MPa). ESDHA appears to be a promising, cost‐effective alternative with favourable cytocompatibility but requires mechanical improvement.

01 Jun 2026·Clinical and Experimental Dental Research

Clinical Evaluation of Three Direct Pulp Capping Materials in Caries‐Induced Pulpitis of Mature Permanent Teeth: A Randomized Controlled Trial

Article

Author: Huang, Lili ; Pan, Yueping ; Li, Yutong ; Ran, Shujun ; Chen, Boshu ; Xia, Wenwei ; Zeng, Kangrui ; Kang, Qiongyi ; Huang, Hong ; Li, Tingting

ABSTRACT:

Objectives:

Direct pulp capping (DPC) preserves pulp vitality in caries‐exposed permanent teeth, but clinical evidence comparing different capping materials and identifying prognostic factors remains limited. This study evaluated the success of DPC with iRoot BP Plus, mineral trioxide aggregate (MTA), and calcium hydroxide (CH), and explored factors associated with treatment outcomes.

Material and Methods:

In this single‐blind, parallel‐group, superiority randomized trial, 120 patients with caries‐induced reversible pulpitis were equally assigned to CH, MTA, or iRoot BP Plus. The primary outcome was 12‐month success, defined by combined clinical and radiographic criteria. Associations between baseline clinical factors and 12‐month success were evaluated. Secondary analyses included success at 3 and 6 months.

Results:

At 12 months, 81 of 120 randomized patients (67.5%) were available for evaluation. The overall success rate was 88.9%. Success rates were 88.5% for iRoot BP Plus ( n = 26), 93.1% for MTA ( n = 29), and 84.6% for CH ( n = 26), with no significant differences between groups ( p = 0.6). Failures were significantly associated with lesions confined to the proximal surface ( p = 0.001) at 12 months, while exposure size > 1 mm ( p = 0.024) and anterior teeth ( p = 0.018) were additional risk factors at 6 months. Kaplan–Meier analysis showed high survival across all groups (log‐rank p = 0.66) and confirmed the influence of these risk factors. No adverse events were reported.

Conclusions:

DPC achieved high short‐term success in mature permanent teeth in MTA, CH, and iRoot BP Plus. Prognostic factors such as caries location, tooth position, and exposure size remain critical for case selection.Trial Registration: number: ChiCTR2100047588; Chinese Clinical Trial Register.

605

News (Medical) associated with Pemetrexed Disodium Hydrate

18 Sep 2026

·www.biospace.com

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective chemoprotection via p53 biomarker strategy; 50% of all cancer patients across multiple tumor types have a p53 mutation Achieved clinical proof-of-concept in Phase 1b study of ALRN-6924 in p53-mutated small cell lung cancer (SCLC) Aileron’s strategy is to ultimately pursue a tumor-agnostic indication -- On track to initiate new Phase 1b placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in second quarter 2021 Planned data readouts: Interim data end of 2021; Topline results mid-2022 -- Aggregate proceeds of $55.7 million from equity fundraises in the first quarter of 2021, together with cash and investments of $13.8 million as of December 31, 2020, expected to support operations into second half of 2023 Strategically investing in CMC, p53 companion diagnostic development and team scale-up to accelerate entry into late-stage development of ALRN-6924 in NSCLC WATERTOWN, Mass., March 24, 2021 (GLOBE NEWSWIRE) --Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2020. “In the fourth quarter of 2020, our Phase 1b trial in SCLC showed that ALRN-6924 has the potential for best-in-class protection against thrombocytopenia, neutropenia and anemia in SCLC patients receiving second-line topotecan chemotherapy. Bolstered by these robust proof-of-concept data, we are on the threshold of initiating our first randomized, double-blind placebo-controlled trial with ALRN-6924 to ‘chemoprotect’ patients with NSCLC who are receiving first-line chemotherapy,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer. Dr. Aivado further commented, “Given our significant capital raises in early 2021, we now believe that we have the resources to strategically invest in CMC, p53 companion diagnostic development and team scale-up, with the explicit goal of rapidly advancing ALRN-6924 into late-stage development for NSCLC following the Phase 1b trial. Bringing selective chemoprotection to NSCLC patients, approximately 50% of whom have a p53 mutation, will be a critical step toward achieving our vision of bringing selective chemoprotection to patients with p53-mutated cancers across all types of cancers and chemotherapies.” Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations, which are present in over half of all cancer patients, to reduce or eliminate chemotherapy-induced side effects while not interfering with chemotherapy’s attack on cancer cells, a novel concept known as chemoprotection. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. The regulatory pathway has been clarified for chemoprotection with the recent U.S. Food and Drug Administration (FDA) approval of the first myeloprotective drug for patients with extensive-stage SCLC.1 Given Aileron’s biomarker approach, designed to ensure selective chemoprotection, coupled with the high prevalence of p53-mutated cancers, the company’s strategy is to ultimately pursue a tumor-agnostic indication for ALRN-6924. Recent and Fourth Quarter and Full Year 2020 Highlights Recent Highlights Announced enrollment expansion for upcoming Phase 1b clinical trial of ALRN-6924 in patients with advanced NSCLC. In February 2021, Aileron announced a 50% expansion of its enrollment target for its upcoming Phase 1b clinical trial of ALRN-6924 in patients with NSCLC undergoing chemotherapy. Aileron plans to enroll 60 patients, increased from the original target of 40 patients, with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed (with or without immune checkpoint inhibitors). Aileron anticipates this enrollment expansion will enable a more robust exploration of ALRN-6924 as a novel chemoprotective agent to prevent toxicities in the NSCLC patient population and better position the company to rapidly advance ALRN-6924 into late-stage clinical development for NSCLC following the Phase 1b trial. In the Phase 1b NSCLC trial, patients will be randomized 1:1 to receive either carboplatin/pemetrexed plus 0.3 mg/kg ALRN-6924 or carboplatin/pemetrexed plus placebo for at least four 21-day treatment cycles. Evaluations will include the proportion of treatment cycles free of severe hematological and other toxicities, transfusions and the use of growth factors, as well as the impact on quality of life. Aileron plans to begin enrolling patients in the NSCLC trial in the second quarter of 2021 and anticipates reporting interim data at the end of 2021 and topline results in mid-2022. Completed Phase 1b trial of ALRN-6924 in patients with SCLC receiving ALRN-6924 prior to topotecan and conducted preliminary evaluation of data from additional cohorts. Since Aileron’s late-breaking presentation of proof-of-concept data from the Phase 1b SCLC trial at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020), the company has completed the trial, including the enrollment of additional cohorts that allowed further analysis of the ALRN-6924/topotecan dosing interval and dose-response relationship. A preliminary evaluation of data from 11 additional patients (n=7 patients receiving 0.3 mg/kg ALRN-6924 six hours before topotecan and n=4 patients receiving 0.2 mg/kg ALRN-6924 twenty-four hours before topotecan) was in line with the data presented in October and with Aileron’s expectation that administering ALRN-6924 at 0.3mg/kg and 24 hours before topotecan remains the optimal dose and schedule in this patient population. Aileron expects to submit final results of the Phase 1b SCLC trial for presentation at a medical conference in the second half of 2021. Raised $55.7 million in aggregate proceeds from the sale of common stock during first quarter 2021, which based on Aileron’s current operating plan, is expected to provide funding into the second half of 2023 and approximately 12 months beyond the anticipated topline results from the NSCLC trial. In January 2021, Aileron completed a registered direct offering of common stock, for a purchase price of $1.10 per share, raising $33.1 million in aggregate net proceeds, after deducting placement agent fees and other offering expenses payable by Aileron. New fundamental investors, including Acorn Bioventures, BVF Partners, L.P., Maven Investment Partners and Grand Oaks Capital, participated in the offering, in addition to several existing Aileron investors, including Satter Medical Technology Partners and Lincoln Park Capital Fund, LLC. In addition to the registered direct offering, since January 1, 2021, Aileron has sold an aggregate of 13,775,399 shares of its common stock for aggregate net proceeds of $22.6 million, after deducting fees and offering expenses, in “at the market” offerings and under its structured equity line with Lincoln Park Capital Fund, LLC. Fourth Quarter and Full Year 2020 Highlights Initiated healthy volunteer study to support long-term clinical development strategy for ALRN-6924. In November 2020, Aileron initiated a study of ALRN-6924 in healthy volunteers to gather data to support its goal to bring chemoprotection to patients with p53-mutated cancer who are undergoing chemotherapy regardless of type of cancer or chemotherapy. The ongoing study is designed to characterize the time to onset, magnitude, and duration of cell cycle arrest in human bone marrow relative to ALRN-6924 administration, with a goal of developing a universal dosing regimen for ALRN-6924 for use as a chemoprotection agent across a range of chemotherapies and p53-mutated tumor indications. Aileron plans to submit results from the healthy volunteer study for presentation at a medical conference in the second half of 2021. Presented proof-of-concept data from Phase 1b SCLC trial of ALRN-6924 in late-breaking presentation at ENA 2020. In October 2020, Aileron presented new positive clinical data from its Phase 1b SCLC trial at the ENA 2020 symposium demonstrating clinical proof of concept that treatment with ALRN-6924 given 24 hours prior to second-line topotecan administration resulted in a protective effect against severe chemotherapy-induced bone marrow toxicities – anemia, thrombocytopenia and neutropenia – in patients with p53-mutated SCLC. The most robust and clinically meaningful protection against toxicities was observed with the 0.3 mg/kg dose of ALRN-6924. Fourth Quarter and Full Year 2020 Financial Results Cash Position: Cash, cash equivalents and investments as of December 31, 2020 were $13.8 million, compared to $18.3 million as of December 31, 2019. The company expects, based on its current operating plan, that its existing cash, cash equivalents and investments will fund operations into the second half of 2023. Research and Development (R&D)Expenses: R&D expenses for the fourth quarter of 2020 were $1.9 million, compared to $4.7 million for the fourth quarter of 2019. The decrease in R&D expenses was primarily due to the completion of the company’s anti-cancer trials in late 2019 and lower spend on the manufacture of ALRN-6924 and research related activities in 2020 as compared to 2019. R&D expenses for the full-year 2020 were $11.2 million, compared to $17.7 million for the prior year. General and Administrative (G&A)Expenses: G&A expenses for the fourth quarter of 2020 were $2.3 million, compared to $2.6 million for the fourth quarter of 2019. The decrease in G&A expenses was largely due to lower spending on employees and facilities in 2020 as compared to 2019. G&A expenses for the full-year 2020 were $9.3 million, compared to $12.3 million for the prior year. Net Loss: Net loss for the fourth quarter of 2020 was $4.9 million, compared to $7.2 million for the fourth quarter of 2019. Net loss for the full-year 2020 was $21.2 million, compared to a net loss of $29.4 million for the prior year. The basic and diluted net loss per share for the fourth quarter of 2020 was $0.12 compared to $0.26 for the fourth quarter of 2019. The basic and diluted net loss per share for the full-year 2020 was $0.61 compared to $1.20 for the full-year 2019. About Aileron Therapeutics Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor activating p53, is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy while ensuring we do not protect cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. Our vision is to bring chemoprotection to patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more. Forward-Looking Statements Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods anticipated or with respect to the matters anticipated; whether initial results of clinical trials will be indicative of final results of those trials or results obtained in future clinical trials, including trials in different indications; whether ALRN-6924 will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will be accepted by and warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether ALRN-6924 will receive approval from regulatory agencies on a timely basis or at all; whether, if ALRN-6924 obtains approval, it will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and our operations; and other factors discussed in the "Risk Factors" section of Aileron's annual report on Form 10-K for the year ended December 31, 2020, filed on March 24, 2021, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise. Investor Contacts: Media Contact: Richard Wanstall, SVP Chief Financial Officer Liz Melone Aileron Therapeutics 617-256-6622 617-995-0900 lmelone@aileronrx.com rwanstall@aileronrx.com Hans C. Vitzthum LifeSci Advisors, LLC. 617-430-7578 hans@lifesciadvisors.com ____________________________ 1 Now FDA approved, G1 Therapeutics’ COSELA™ (trilaciclib) is intended to help protect bone marrow in patients with extensive-stage SCLC when administered prior to chemotherapy. Aileron Therapeutics, Inc. Balance Sheet Data (In thousands) December 31, 2020 December 31, 2019 Cash, cash equivalents and investments $ 13,805 $ 18,278 Working capital $ 12,366 $ 13,711 Total assets $ 16,341 $ 26,473 Accumulated deficit $ (219,292 ) $ (198,135 ) Total stockholders' equity $ 12,162 $ 16,048 Aileron Therapeutics, Inc. Condensed Statement of Operations (In thousands, except share and per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2020 2019 2020 2019 Revenue $ - $ - $ - $ - Operating expenses: Research and development 1,925 4,709 11,166 17,663 General and administrative 2,267 2,639 9,330 12,293 Total Operating expenses 4,192 7,348 20,496 29,956 Loss from operations (4,192 ) (7,348 ) (20,496 ) (29,956 ) Interest income (738 ) 112 (661 ) 587 Net loss (4,930 ) (7,236 ) (21,157 ) (29,369 ) Net loss per share — basic and diluted $ (0.12 ) $ (0.26 ) $ (0.61 ) $ (1.20 ) Weighted average common shares outstanding—basic and diluted 40,997,759 27,810,358 34,866,690 24,535,454

Financial StatementFirst in ClassAACR

14 Sep 2026

·www.biospace.com

Johnson & Johnson’s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea , Sept. 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) exon 20 insertion (Ex20ins) mutations. Patients treated with the combination achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone. The combination extended median OS by more than six months, despite 76 percent of eligible patients in the chemotherapy arm crossing over to second-line RYBREVANT after disease progression. This represents the longest reported median OS in this patient population, which is nearly twice the historical median. 1 These results were presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) (Late-breaking Abstract #PL.03.03). Resetting survival expectations for patients with historically poor outcomes EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations. 2 Unlike more common EGFR mutations (exon 19 deletions and L858R), exon 20 insertion mutations have been difficult to treat with targeted medicines, leaving patients with few treatment options, challenging side effects and poorer outcomes. 3 Historically, median overall survival has ranged from approximately 16 to 24 months, with five-year survival reported at just eight percent. 4,5,6 RYBREVANT is a first-in-class bispecific antibody designed to dual-target EGFR and mesenchymal-epithelial transition (MET), two key drivers of tumor growth and treatment resistance, while also engaging the immune system. 7,8,9,10 It is currently approved for use in patients with EGFR -mutated advanced NSCLC across common (exon 19 deletions and exon 21 L858R substitution mutations) and exon 20 insertion mutations, in the first- and second-line settings. 11 Expert and company perspectives on longer survival in historically difficult-to-treat lung cancer "We've come a long way in treating EGFR exon 20 insertion-positive lung cancer, and these results demonstrate the lasting impact RYBREVANT plus chemotherapy can have in helping patients live longer," said Dr. Chul Kim, M.D., M.P.H.,* Director of Thoracic Oncology, MedStar Georgetown University Hospital. "Patients are continuing treatment years after they started, which speaks to the durability of this approach and its value as a first-line treatment for this disease." "We have long believed RYBREVANT could transform the outlook for patients with EGFR -mutated lung cancer by addressing key drivers of disease progression and treatment resistance," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "With the longest survival seen in this patient population, these results add to the growing body of evidence across common, atypical and exon 20 insertion EGFR mutations and further establish the regimen as a backbone therapy." Detailed overall survival results In the protocol-specified final analysis, RYBREVANT plus chemotherapy demonstrated a median OS of nearly three years (34.3 months) compared to approximately two years (27.9 months) for chemotherapy alone (hazard ratio [HR], 0.87; 95 percent confidence interval [CI], 0.66-1.14; P =0.307). A prespecified analysis accounting for crossover to RYBREVANT in the chemotherapy arm showed a significant overall survival benefit with RYBREVANT plus chemotherapy, reducing the risk of death by 43 percent (HR, 0.57; 95 percent CI, 0.39-0.82; nominal P =0.003). 1 Long-term follow-up provides further evidence of durable benefit, with RYBREVANT plus chemotherapy extending progression-free survival through second disease progression (PFS2) by more than 10 months compared with chemotherapy alone (28.3 vs. 17.5 months; HR, 0.59; 95 percent CI, 0.45-0.77; nominal P 2% of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each). In PAPILLON (n=151), the most common ARs (≥20%) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%). In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified. RYBREVANT as a Single Agent In CHRYSALIS (n=129), the most common ARs (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%). Serious ARs occurred in 30% of patients, with those occurring in ≥2% of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death. LAZCLUZE DRUG INTERACTIONS Avoid concomitant use of LAZCLUZE with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4. Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate. Please see full Prescribing Information for RYBREVANT FASPRO , RYBREVANT and LAZCLUZE . cp-491009v2 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at or at . Follow us at @JNJInnovMed . Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT ® (amivantamab-vmjw). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , , or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. * Dr. Chul Kim, M.D., M.P.H., has served as a consultant to Johnson & Johnson; he has not been paid for any media work. † RECIST (version 1.1) refers to Response Evaluation Criteria in Solid Tumors, which is a standard way to measure how well solid tumors respond to treatment and is based on whether tumors shrink, stay the same or get bigger. ‡ The NCCN content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. § See the NCCN Guidelines for detailed recommendations, including other treatment options. || The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories. Source: Johnson & Johnson 1 Kim C, et al. First-line amivantamab-chemotherapy vs chemotherapy in NSCLC with EGFR exon 20 insertions: Overall survival from PAPILLON. Presented at: IASLC 2026 World Conference on Lung Cancer; 2026; Seoul. 2 Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity and clinicopathologic characteristics. Molecular Cancer Therapeutics. 2013;12(2):220-229. 3 Brazel D, et al. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs . 2022 Nov;36(6):717-729. doi: 10.1007/s40259-022-00556-4. 4 Ou SI, et al. Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations. JTO Clin Res Rep . 2023;4(10):100558. 5 Bazhenova L, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer . 2021;162:154–161 6 Chouaid C, et al. A real-world study of patients with advanced non-squamous non-small cell lung cancer with EGFR exon 20 insertion: clinical characteristics and outcomes. Target Oncol . 2021;16(6):801-811. 7 Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res . 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833 8 Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR /cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther . 2020;19(10):2044-2056. doi:10.1158/1535-7163.MCT-20-0071 9 Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR -MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov . 2020;10(8):1194-1209. doi:10.1158/2159-8290.CD-20-0116 10 Soo R, et al. Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer. Lung Cancer . Published online May 22, 2026. doi:10.1016/S0169-5002(26)00466-6. 11 RYBREVANT [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 12 Zhou C, Tang KJ, Cho BC, et al; PAPILLON Investigators. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039-2051. doi:10.1056/NEJMoa2306441. 13 ClinicalTrials.gov. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor ( EGFR ) Exon 20 Insertions (PAPILLON). Accessed September 2026. 14 The World Health Organization. Cancer. Accessed September 2026. 15 American Cancer Society. What is Lung Cancer? Accessed September 2026. 16 Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol . 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18. 17 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. 2021 World Conference on Lung Cancer Annual Meeting; January 29, 2021. 18 Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol . 37:97-104. 19 Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore. 20 Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget . 2016;7(48):78985-78993. 21 Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res . 2015;5(9):2892-2911. 22 American Lung Association. EGFR and Lung Cancer. Accessed September 2026. 23 Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER web site. 24 Lin JJ, et al. Five-year survival in EGFR -mutant metastatic lung adenocarcinoma treated with EGFR -TKIs. J Thorac Oncol . 2016 Apr;11(4):556-65. 25 Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore. 26 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Non-Small Cell Lung Cancer V.7.2026 © National Comprehensive Cancer Network, Inc. All rights reserved. Accessed September 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. 27 RYBREVANT FASPRO [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. Media contact: Oncology Media Relations oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com U.S. Medical Inquiries: +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson

Clinical ResultPhase 2Phase 3ASCODrug Approval

14 Sep 2026

·allsci.com

J&J's Rybrevant shows numerical OS gain in PAPILLON, but final analysis misses significance

Final overall survival (OS) data from the PAPILLON study showed a numerical survival advantage for amivantamab (Rybrevant) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer (NSCLC), although the protocol-specified analysis did not reach statistical significance. Median OS was 34.3 months with the amivantamab combination versus 27.9 months with chemotherapy, according to results presented at the Presidential Symposium of the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul. The final OS analysis fulfills a postmarketing commitment agreed with the FDA when the first-line combination was approved in 2024, requiring J&J to complete PAPILLON and report mature survival data to further characterize the treatment’s clinical benefit. The final OS analysis produced a hazard ratio of 0.87 (95% CI 0.66–1.14; P=0.307). Interpretation is complicated by extensive crossover: 76% of eligible patients in the chemotherapy arm received second-line amivantamab after disease progression, likely reducing the observed difference between the randomized groups. In a prespecified crossover-adjusted analysis, the hazard ratio for death was 0.57 (95% CI 0.39–0.82; nominal P=0.003), corresponding to a 43% reduction in the modeled risk of death. That adjusted result should be interpreted separately from the protocol-specified randomized OS analysis. Of patients assigned to amivantamab plus chemotherapy, 12% remained on first-line treatment at the clinical cutoff, compared with none in the chemotherapy arm. Progression-free survival through second disease progression (PFS2) also favored the combination, at 28.3 months versus 17.5 months (HR 0.59; P<0.0001), adding evidence that the initial treatment benefit extended beyond first progression. The safety profile was consistent with previous PAPILLON reports, with no new signals identified. The most common treatment-related adverse events included paronychia (60%), neutropenia (60%), and rash (58%). Amivantamab is an EGFR/MET bispecific antibody designed to inhibit signaling through both receptors and address resistance mechanisms associated with EGFR exon 20 insertion mutations. The US FDA approved amivantamab plus carboplatin-pemetrexed for first-line treatment of EGFR ex20ins-mutated advanced NSCLC in March 2024 after the primary PAPILLON analysis showed a 60% reduction in the risk of disease progression or death versus chemotherapy. A subcutaneous formulation, Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), received US FDA approval in December 2025 across amivantamab indications. PAPILLON previously served as the confirmatory trial that converted Rybrevant’s original 2021 accelerated approval to traditional approval in 2024, while also establishing the amivantamab-chemotherapy combination as a first-line option. The final OS findings are therefore mixed. The randomized analysis did not demonstrate a statistically significant survival benefit, while the prespecified crossover-adjusted analysis suggests that extensive post-progression use of amivantamab in the control arm may have attenuated the observable treatment effect. The longer PFS2 and proportion of patients remaining on first-line therapy also support durable disease control, but do not override the negative protocol-specified OS result. Competition in EGFR exon 20 insertion-mutated NSCLC has intensified since PAPILLON's primary readout. Dizal (Jiangsu) Pharmaceutical's Zegfrovy (sunvozertinib), an oral EGFR tyrosine kinase inhibitor, received US FDA accelerated approval in July 2025 for previously treated disease following platinum chemotherapy. Taiho Pharmaceutical and Cullinan Therapeutics are also advancing zipalertinib into the first-line setting after the Phase III REZILIENT3 trial showed median progression-free survival of 14.5 months with zipalertinib plus chemotherapy versus 8.5 months with chemotherapy alone. The emerging competitive landscape therefore pits amivantamab's established first-line position against oral mutant-selective EGFR inhibitors moving into earlier treatment, while PAPILLON's final OS data provide supportive but not statistically definitive evidence for a survival advantage. Spot something wrong? Report an issue with this article

Clinical ResultPhase 3Drug ApprovalAccelerated Approval

100 Deals associated with Pemetrexed Disodium Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D07472	Pemetrexed Disodium Hydrate	L01BA04	DB00642

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma	Brazil	Libbs Farmacêutica Ltda.	10 Sep 2012
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Brazil	Libbs Farmacêutica Ltda.	10 Sep 2012
Unresectable Pleural Malignant Mesothelioma	Brazil	Libbs Farmacêutica Ltda.	10 Sep 2012
Non-squamous non-small cell lung cancer	United States	Eli Lilly & Co.	02 Jul 2009
Mesothelioma	United States	Eli Lilly & Co.	19 Aug 2004
Non-Small Cell Lung Cancer	United States	Eli Lilly & Co.	19 Aug 2004
Locally Advanced Lung Non-Small Cell Carcinoma	Australia	Eli Lilly Australia Pty Ltd.	30 Jun 2004
metastatic non-small cell lung cancer	Australia	Eli Lilly Australia Pty Ltd.	30 Jun 2004
Malignant Pleural Mesothelioma	United States	Eli Lilly & Co.	04 Feb 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	United States	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	China	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Japan	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Australia	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Austria	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Belgium	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Brazil	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Canada	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Czechia	Eli Lilly & Co.	21 Dec 2023
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	Denmark	Eli Lilly & Co.	21 Dec 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04895735 (MC200708, CTgov)	Phase 2	Salivary gland cancer recurrent \| Metastatic salivary gland cancer \| Adenoid Cystic Carcinoma	45	pembrolizumab+pemetrexed disodium (Cohort A (Adenoid Cystic Carcinoma))	cgeiixsnjl = jsmqyyejcp bewiywdqsw (xmvjxggcej, yikpjpnjow - ljljihwqwv) View more	-	04 Jun 2026
				pembrolizumab+pemetrexed disodium (Cohort A1 (ACC Patients Enrolled Starting With MCCC Amendment 3))	cgeiixsnjl = ehpfiqkttg bewiywdqsw (xmvjxggcej, aidzusquwr - uwdpuuicjo)
NCT04163432 (STAGGER, CTgov)	Phase 2	metastatic non-small cell lung cancer \| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	43	Carboplatin+Durvalumab+Pemetrexed (Arm A: Chemo-Immuno)	msgwtcvyey = jsfapdlsoi arvqpmbgws (dwzwbqqgit, mlxrjhucav - yauyxadfbx) View more	-	19 May 2026
				Carboplatin+Durvalumab+Pemetrexed (Arm B: Immuno-Chemo)	msgwtcvyey = vjurazrfoz arvqpmbgws (dwzwbqqgit, nfkwxjhyxa - fsdomfqofg) View more
NCT04245085 (ETOP 15-19 ABC-lung \| ETOP ABC-lung \| ABC-lung, CTgov)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	95	Carboplatin+Paclitaxel+Atezolizumab+Bevacizumab (Arm A)	cisltxwbwo = rpfinkkxsg okbdprxvgt (rqtujjcleh, zcmfqmndta - hkixfaheff) View more	-	12 May 2026
				Atezolizumab+Bevacizumab+Pemetrexed (Arm B)	cisltxwbwo = huoxmttdtl okbdprxvgt (rqtujjcleh, sscxfjnvhp - bhojdbspuu) View more
NCT04042558 (GFPC 06-2018, CTgov)	Phase 2	Non-small cell lung cancer stage IIIB \| metastatic non-small cell lung cancer \| Non-squamous non-small cell lung cancer	150	Carboplatin+Atezolizumab+Bevacizumab+Pemetrexed (Cohort With Bevacizumab)	qyljexfjez = xcduoqyaft tkephxiuye (unjvbyqjrx, ibvmunbizt - kkwalcoqpe) View more	-	12 May 2026
				Carboplatin+Atezolizumab+Pemetrexed (Cohort Without Bevacizumab)	qyljexfjez = ynnhjzkusw tkephxiuye (unjvbyqjrx, mdqyvqtuhg - wruvvpjtkn) View more
NCT06630325 (CTgov)	Phase 2	Ovarian Cancer \| Advanced Malignant Solid Neoplasm \| Pancreatic Cancer ... View more	6	Survey Administration+Abemaciclib+Gemcitabine (Arm I (Abemaciclib, Gemcitabine))	visnlsngak(tdaxchklgc) = qrahgplrli egavblbjdz (joskbotzop, slbutiimyp - ykxsgtlzlb) View more	-	28 Apr 2026
				Survey Administration+abemaciclib+Pemetrexed (Arm II (Abemaciclib, Pemetrexed))	visnlsngak(tdaxchklgc) = fusfimelrz egavblbjdz (joskbotzop, lzirthrhhx - yymxgfulwi) View more
NCT03366766 (CTgov)	Phase 2	Non-small cell lung cancer stage I \| Resectable Lung Non-Small Cell Carcinoma \| Non-small cell lung cancer stage IIIA ... View more	14	Nivolumab+cisplatin+Pemetrexed Disodium (Cohort I (Nivolumab, Cisplatin, Pemetrexed Disodium))	uuyeavmuzr = wnqpvitcka zhxkgdgzgd (zziqypxskh, toqywbfvuk - kbywnlcict) View more	-	20 Feb 2026
				nivolumab+Gemcitabine Hydrochloride (Cohort I (Nivolumab, Cisplatin, Gemcitabine Hydrochloride))	puzqcgsmlj = zluainkwio htpmtdmfky (kvtvesafor, tqtgrwkavd - pbkbbctjig)
NCT04765059 (COMPEL, CTgov)	Phase 3	Non-Small Cell Lung Cancer \| Squamous non-small cell lung cancer \| Recurrent Non-Small Cell Lung Cancer	98	Carboplatin+Pemetrexed+Cisplatin+Osimertinib (AZD9291) (Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin)	uzyjcazrvo(vokdnhtoji) = wzhkgdaazh ipkooddjgh (ldysxuzxyi, exdhiexgdi - qpxnrdyiwn) View more	-	13 Jan 2026
				Placebo+Carboplatin+Pemetrexed+Cisplatin+Osimertinib (AZD9291) (Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin)	uzyjcazrvo(vokdnhtoji) = riqgnekpdi ipkooddjgh (ldysxuzxyi, vesxpimnjr - uitiippcjs) View more
ESMO_ASIA2025	Not Applicable	EGFR-mutated non-small Cell Lung Cancer First line EGFR-mutant	1,050	Gefitinib + pemetrexed-platinum chemotherapy	jcdybciumq(pqwbdtowjy): RR = 1.03 (95.0% CI, 0.79 - 1.34), P-Value = 0.81 View more	Positive	05 Dec 2025
				Gefitinib monotherapy
NCT04967417 (PHOEBS, CTgov)	Phase 2	Non-Small Cell Lung Cancer \| metastatic non-small cell lung cancer \| Brain metastases	13	Carboplatin+Pembrolizumab+Pemetrexed (Non-squamous Cell Carcinoma)	pntmlncygg(tnmswqjsao) = jlcvbaanla lvsadzwpjf (avyapnnhkf, tefjwfpmij - umawclnyix) View more	-	09 May 2025
				Carboplatin+Paclitaxel+Pembrolizumab (Squamous Cell Carcinoma)	pntmlncygg(tnmswqjsao) = zuaxtvlgto lvsadzwpjf (avyapnnhkf, nmcyphrzga - qdtsongqpq) View more
NCT03137771 (NRG-LU002, CTgov)	Phase 2	metastatic non-small cell lung cancer \| Recurrent Non-Small Cell Lung Cancer	218	Erlotinib Hydrochloride+Gemcitabine+Docetaxel+Pembrolizumab+Pemetrexed Disodium (Arm 1 (Systemic Maintenance Chemotherapy))	njtsstdyky(hcnvqmmkyr) = nlclkzpwzq wtqwbszfim (ekfcoydsph, zcsyyqyqxl - xxwshufvqf) View more	-	11 Mar 2025
				Stereotactic Body Radiation Therapy (SBRT)+Erlotinib Hydrochloride+Gemcitabine+Docetaxel+Pembrolizumab+Pemetrexed Disodium (Arm 2 (LCT + Systemic Maintenance Chemotherapy))	njtsstdyky(hcnvqmmkyr) = qwyofeuwza wtqwbszfim (ekfcoydsph, quqmqgazqe - fdgeuzfgzo) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis